Alabama Cancer Congress


Within several years of establishment, the Alabama Cancer Congress has become the leading representative body of providers for cancer medicine in the state of Alabama. The continued commitment of promoting education, advocacy, and a sense of community for professional medical cancer organizations, has led us to be recognized by the Legislature within the State.

Our website provides information regarding statewide oncologic organizations, links to oncology resources, and recent meeting presentations. Each member of the Alabama Cancer Congress executive board encourages feedback and collaboration from our members. In this dynamic healthcare environment we must continue to provide excellent patient care while supporting the interests of cancer medicine providers in Alabama.

Our main mission is to serve as a sustainable inclusive representative body of all providers of cancer medicine in the state of Alabama – promoting education, advocacy and sense of community.


ACC corporate membership provides businesses with the opportunity to align themselves with medical, radiation, gynecologic and neurological oncology practices throughout Alabama. Advertisers are able to reach the oncologists and practice decision makers via advertising in society newsletters, websites, and at business, educational and legislative conferences.


Join Today

Economic Cost of Cancer in U.S. Tops $94B Annually According to a Study
State-by-state variations in cancer deaths suggest that effective cancer prevention and treatment could yield economic benefits, according to a study published in JAMA Oncology.

Click here for more.

COA Launches Major National Campaign to Stop PBM Abuses and Highlight Patient Horror Stories
COA recently launched a major national campaign to highlight the negative impact of pharmacy benefit managers (PBMs) on patients with cancer. The “PBM Abuses” campaign will ensure that PBM middlemen's abuse of patients with cancer is not lost in policy deliberations in Washington.

Click here for more

CMS' "Fail First" Step Therapy Policy Means Medicare Patients with Cancer Will Face More Dangerous Delays and Denials
Earlier this month, the Centers for Medicare & Medicaid Services (CMS) codified its decision to allow MA plans to use “fail first” step therapy for new starts of Part B drugs for cancer and other serious diseases. The Trump administration’s decision to finalize step therapy in MA plans means that Medicare patients with cancer will face nightmares of delays and denials while trying to access their physician-prescribed treatments.

Click here for more


Upcoming Events

2019 ACC Fall Conference
October 12, 2019
Birmingham Marriott
Registration opens soon.


Janssen provides discussion paper for 2020 Medicare Hospital Inpatient Prospective Payment System (IPPS) Proposed Rule. 

The CMS fact sheet is available here.  In the FY 2020 IPPS Proposed Rule, CMS addresses how the agency proposes to pay for CAR T-cell therapy administered on an inpatient basis.

Click here for more

CDC Issues Key Clarification on Guideline for Prescribing Opioids for Chronic Pain
Agency Clarifies CDC Guideline Not Meant to Limit Access to Appropriate Pain Management for Individuals with Cancer, Sickle Cell Disease

Click here for more.


Learn more about the big changes to the ASH Scholar Award program.

More people are now eligible for the ASH Scholar Awards than ever before. The new Fellow to Faculty Scholar Award offers financial support to those preparing to compete for independent faculty-level positions in the next two to three years.

Click here for more